Protecting Axons Protecting Patients Creating breakthrough therapeutics for neurological diseases learn more Disarm is conducting a chemotherapy-induced peripheral neuropathy (CIPN) natural history study (EPIPHANY). This prospective observational study is being conducted across multiple sites in the U.S. and will characterize CIPN disease course and associated biomarkers. Learn More + Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo October 22, 2019 press release + Disarm Therapeutics Announces First Subject Enrolled in EPIPHANY Natural History Study of Chemotherapy-Induced Peripheral Neuropathy (CIPN) September 4, 2019 press release + A New Approach to Treating Multiple Sclerosis News +
